全文获取类型
收费全文 | 649篇 |
免费 | 37篇 |
国内免费 | 13篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 16篇 |
基础医学 | 69篇 |
口腔科学 | 3篇 |
临床医学 | 29篇 |
内科学 | 88篇 |
皮肤病学 | 7篇 |
神经病学 | 76篇 |
特种医学 | 5篇 |
外科学 | 39篇 |
综合类 | 35篇 |
预防医学 | 12篇 |
眼科学 | 1篇 |
药学 | 264篇 |
中国医学 | 15篇 |
肿瘤学 | 35篇 |
出版年
2023年 | 11篇 |
2022年 | 17篇 |
2021年 | 24篇 |
2020年 | 15篇 |
2019年 | 30篇 |
2018年 | 28篇 |
2017年 | 19篇 |
2016年 | 21篇 |
2015年 | 22篇 |
2014年 | 44篇 |
2013年 | 85篇 |
2012年 | 41篇 |
2011年 | 63篇 |
2010年 | 38篇 |
2009年 | 28篇 |
2008年 | 35篇 |
2007年 | 37篇 |
2006年 | 20篇 |
2005年 | 25篇 |
2004年 | 12篇 |
2003年 | 24篇 |
2002年 | 9篇 |
2001年 | 14篇 |
2000年 | 4篇 |
1999年 | 4篇 |
1998年 | 4篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 1篇 |
1988年 | 1篇 |
1986年 | 4篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1978年 | 1篇 |
排序方式: 共有699条查询结果,搜索用时 250 毫秒
11.
目的 观察雷洛昔酚是否能诱发出催乳素瘤的动物模型以及对PRL水平的影响,以研究雷洛昔酚对大鼠垂体的作用。方法雌性Wistar大鼠切除卵巢后,分别在皮下埋植含有雷洛昔酚、雌激素和空白硅胶管,术后8周处死大鼠,检测大鼠体重变化、垂体重量变化、血清催乳素(PRL)水平和垂体组织学变化。结果雷洛昔酚组与阴性对照组大鼠体重无明显统计学差异,与雌激素组大鼠体重具有统计学差异(P<0.05);雷洛昔酚组与阴性对照组大鼠垂体重相比无明显差异,与雌激素组大鼠垂体重相比具有统计学差异(P<0.05);雌激素组大鼠血清PRL水平最高,阴性对照组血清PRL水平最低,雷洛昔酚组介于两者之间,分别与雌激素组、对照组相比较差异均具有统计学意义(P<0.05);雷洛昔酚组与对照组垂体病理为正常细胞形态,雌激素组垂体病理为PRL瘤表现。结论雷洛昔酚对大鼠垂体有一定的影响,但不能诱发催乳素瘤。 相似文献
12.
色素失禁症( IP)是一种罕见的X-连锁显性遗传性皮肤病。其致病基因主要为B细胞编码κ轻链多肽抑制基因(IKBKG), NF-κB关键调节因子(NEMO)基因。该文综合分析1例IP患儿的临床资料,并提取患儿及其父母的外周血DNA,先用多重聚合酶链反应( PCR)扩增方法检测频发突变共有序列NEMOΔ4-10缺失,再用跨越断裂点PCR方法扩增NEMO或ΔNEMO基因特异性缺失,并对PCR产物进行序列分析验证。患儿存在NEMO基因外显子4-10的缺失;该突变遗传自其表型正常的母亲。 NEMO 基因外显子4-10的缺失是该患儿的致病性突变。该研究进一步证实了NEMOΔ4-10缺失这种基因组重排是IP患者最常见的突变类型。 相似文献
13.
Sambrook P 《Best Practice & Research: Clinical Rheumatology》2005,19(6):975-981
Clinical trials have demonstrated that the selective estrogen receptor modulator raloxifene can reduce the risk of vertebral fracture, but have not unequivocally demonstrated an effect on non-vertebral fracture. Consequently it is recommended that raloxifene be used mainly in postmenopausal women with milder osteoporosis as a preventive measure or for treatment in those with predominantly spinal osteoporosis. Since the effects of raloxifene on bone mineral density and bone turnover may reverse soon after cessation, it is recommended that raloxifene be used as long-term therapy for 5-10 years. Because of its quicker offset, use of raloxifene may have advantages over potent bisphosphonates if use of anabolic agents are contemplated in an individual patient. 相似文献
14.
15.
Symptoms related to vaginal atrophy are a significant problem for postmenopausal women and estrogen has been the gold standard for its treatment. A number of recent reviews of vaginal estrogen products are available. This review will, therefore, focus on other products and potential products for this indication, including the tissue selective estrogen complex and selective estrogen receptor modulators. Additionally, lesser-studied approaches will be discussed. 相似文献
16.
17.
18.
Heiko Rühl Lars Schröder Jens Müller Rolf Fimmers Shorena Sukhitashvili Julia Welz Walther C. Kuhn Johannes Oldenburg Christian Rudlowski Bernd Pötzsch 《Thrombosis research》2014
Introduction
The estrogen antagonist tamoxifen (TAM) increases the thrombotic risk similar to estrogen containing oral contraceptives (OC). In OC users this risk is attributed to alterations of hemostasis resulting in acquired resistance to activated protein C (APC). TAM-induced APC resistance has not been reported yet.Materials and Methods
Blood samples were collected prospectively from women with breast cancer before (n = 25) and monthly after start of adjuvant TAM treatment (n = 75). APC resistance was evaluated on basis of the effect of APC on the endogenous thrombin generation potential. To detect increased in vivo APC generation APC plasma levels were measured using a highly sensitive oligonucleotide-based enzyme capture assay. Routine hemostasis parameters were measured additionally.Results
APC sensitivity decreased by 41% (p = 0.001) compared to baseline after one month of TAM application and remained significantly decreased during the study period. Free protein S increased (p = 0.008) while other analyzed procoagulant factors, inhibitors, and activation markers of coagulation decreased or did not change significantly. In five patients the APC concentration increased to non-physiological levels but an overall significant increase of APC was not observed.Conclusions
This is the first study showing acquired APC resistance under TAM therapy. Acquired APC resistance might explain the increased thrombotic risk during TAM treatment. Observed changes of hemostasis parameters suggest different determinants of TAM-induced APC resistance than in OC-induced APC resistance. The presence of acquired APC resistance in TAM patients warrants further evaluation if these patients may benefit from antithrombotic prophylaxis in the presence of additional thrombotic risk factors. 相似文献19.
Estrogens regulate key features of metabolism, including food intake, body weight, energy expenditure, insulin sensitivity, leptin sensitivity, and body fat distribution. There are two ‘classical’ estrogen receptors (ERs): estrogen receptor alpha (ERS1) and estrogen receptor beta (ERS2). Human and murine data indicate ERS1 contributes to metabolic regulation more so than ESR2. For example, there are human inactivating mutations of ERS1 which recapitulate aspects of the metabolic syndrome in both men and women. Much of our understanding of the metabolic roles of ERS1 was initially uncovered in estrogen receptor α-null mice (ERS1−/−); these mice display aspects of the metabolic syndrome, including increased body weight, increased visceral fat deposition and dysregulated glucose intolerance. Recent data further implicate ERS1 in specific tissues and neuronal populations as being critical for regulating food intake, energy expenditure, body fat distribution and adipose tissue function. This review will focus predominantly on the role of hypothalamic ERs and their critical role in regulating all aspects of energy homeostasis and metabolism. 相似文献
20.